Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsNovo Nordisk's CagriSema — a once-weekly combo of cagrilintide and semaglutide — is proving to be a strong contender in the obesity and type 2 diabetes space. In the REIMAGINE 5 trial, CagriSema delivered 12.4% weight loss vs. 9.1% for tirzepatide in adults with T2D. A separate trial (REDEFINE 9) showed 21% body weight reduction in people with overweight or obesity without diabetes — and an FDA decision is expected by Q4 2026.
Novo Nordisk's investigational CagriSema — a fixed-dose, once-weekly injectable combining the amylin receptor agonist cagrilintide with GLP-1 receptor agonist semaglutide — is stacking up impressively against the competition. Topline results from two new trials show it outperforms tirzepatide (Mounjaro/Zepbound) for weight loss in adults with type 2 diabetes, and delivers striking results in people with obesity who don't have diabetes.
In the REIMAGINE 5 trial, adults with T2D on CagriSema 1 mg/1 mg lost 12.4% of body weight at 60 weeks, compared to 9.1% for those on tirzepatide 5 mg — while HbA1c reductions were comparable between the two drugs. Meanwhile, in REDEFINE 9, adults with overweight or obesity (without diabetes) on CagriSema 1 mg/1 mg lost 21% of their body weight at 68 weeks, versus just 2% on placebo. The drug also improved systolic blood pressure, waist-to-height ratio, and fasting lipid profiles.
By the Numbers:
Why it matters: With an FDA ruling on the horizon, CagriSema could soon reshape the obesity and T2D treatment landscape — offering a new option that, at least at lower doses, appears to edge out tirzepatide on weight loss. For clinicians managing these patients, more potent and well-tolerated tools may be on the way.
